open access

Vol 15, No 2 (2010)
Published online: 2010-03-01
Submitted: 2009-07-22
Get Citation

Whole abdominal radiotherapy in ovarian cancer

Alberto Biete, Izaskun Valduvieco, Angels Rovirosa, Blanca Farrús, Francesc Casas, Carlos Conill
DOI: 10.1016/j.rpor.2010.02.004
·
Rep Pract Oncol Radiother 2010;15(2):27-30.

open access

Vol 15, No 2 (2010)
Published online: 2010-03-01
Submitted: 2009-07-22

Abstract

Objectives

The aim of the study was to evaluate the clinical outcome and toxicity after adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.

Material and methods

Ten patients with optimal cytoreduced ovarian cancer, with a mean age of 58 years (40–70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and adjuvant chemotherapy (9/10). The total radiation dose was 22.5[[ce:hsp sp="0.25"/]]Gy in the whole abdomen and 42–45[[ce:hsp sp="0.25"/]]Gy in the pelvis.

Results

The mean follow-up was 8 years. The 5-year actuarial disease-free survival (DFS) was 60%, and the overall survival (OS) was 70%. Four patients had disease recurrence. The sites of recurrence were the abdomen in 2 patients and distant metastases in the other 2 patients (liver and brain metastasis). Gastrointestinal toxicity was as follows: acute 3/10 grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small bowel obstruction (SBO) that required surgery.

Conclusions

Whole abdominal radiotherapy after surgery and platinum-based chemotherapy achieves high locoregional disease control with an acceptable risk of acute toxicity.

Abstract

Objectives

The aim of the study was to evaluate the clinical outcome and toxicity after adjuvant whole abdominal radiotherapy (WART) in patients with ovarian cancer.

Material and methods

Ten patients with optimal cytoreduced ovarian cancer, with a mean age of 58 years (40–70) and stage Ic: 4, stage II: 2, stage III: 4, were treated with WART and adjuvant chemotherapy (9/10). The total radiation dose was 22.5[[ce:hsp sp="0.25"/]]Gy in the whole abdomen and 42–45[[ce:hsp sp="0.25"/]]Gy in the pelvis.

Results

The mean follow-up was 8 years. The 5-year actuarial disease-free survival (DFS) was 60%, and the overall survival (OS) was 70%. Four patients had disease recurrence. The sites of recurrence were the abdomen in 2 patients and distant metastases in the other 2 patients (liver and brain metastasis). Gastrointestinal toxicity was as follows: acute 3/10 grades I and II, and late toxicity: 2/10 grades I and II, and only 1 patient developed small bowel obstruction (SBO) that required surgery.

Conclusions

Whole abdominal radiotherapy after surgery and platinum-based chemotherapy achieves high locoregional disease control with an acceptable risk of acute toxicity.

Get Citation

Keywords

Ovarian cancer; Whole abdominal radiotherapy; Gastrointestinal toxicity

About this article
Title

Whole abdominal radiotherapy in ovarian cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 15, No 2 (2010)

Pages

27-30

Published online

2010-03-01

DOI

10.1016/j.rpor.2010.02.004

Bibliographic record

Rep Pract Oncol Radiother 2010;15(2):27-30.

Keywords

Ovarian cancer
Whole abdominal radiotherapy
Gastrointestinal toxicity

Authors

Alberto Biete
Izaskun Valduvieco
Angels Rovirosa
Blanca Farrús
Francesc Casas
Carlos Conill

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl